Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 7

1.

Extensively drug resistant tuberculosis

Extensively drug resistant TB are strains of TB that are resistant to at least rifampicin and isoniazid, and also resistant to a fluoroquinolone and to at least one of the three injectable TB drugs, capreomycin, kanamycin and amikacin. [from SNOMEDCT_US]

MedGen UID:
321809
Concept ID:
C1827301
Disease or Syndrome
2.

Comtan

MedGen UID:
163743
Concept ID:
C0876730
Organic Chemical; Pharmacologic Substance
3.

Tuberculosis

A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use. [from NCI]

MedGen UID:
22513
Concept ID:
C0041296
Disease or Syndrome
4.

Drug resistant tuberculosis

MedGen UID:
61616
Concept ID:
C0206525
Disease or Syndrome
5.

Catechol-O-methyltransferase inhibitor

Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. [from MeSH]

MedGen UID:
670998
Concept ID:
C0595267
Pharmacologic Substance
6.

Tolcapone

A benzophenone derivative and a catechol-O-methyltransferase (COMT) inhibitor. Tolcapone selectively and reversibly inhibits COMT, an enzyme that catalyzes the metabolism of biologically active catechols and their hydroxylated metabolites by transferring the methyl group of S-adenosyl-L-methionine to the phenolic group of catechol-containing substrates. When given in conjunction with a peripheral dopa decarboxylase inhibitor and levodopa, tolcapone may prevent the metabolism of levodopa to 3-methoxy-4-hydroxy- L-phenylalanine (3-OMD) in the brain and peripheral tissues leading to increased bioavailability and enhancement of delivery to the central nervous system (CNS) of levodopa. [from NCI]

MedGen UID:
70057
Concept ID:
C0246330
Organic Chemical; Pharmacologic Substance
7.

Entacapone

A nitrocatechol compound with anti-parkinsonian property. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure including dihydroxyphenylalanine (DOPA), catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone prevents the metabolism and inactivation of adjunct drugs, thereby increasing the bioavailability of these compounds by facilitating their passage across the blood-brain barrier. [from NCI]

MedGen UID:
56842
Concept ID:
C0165921
Organic Chemical; Pharmacologic Substance
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center